Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Instruments Regulatory News (OXIG)

Share Price Information for Oxford Instruments (OXIG)

Share Price is delayed by 15 minutes
Get Live Data
3,070.00    52.00 (1.72%)
Bid:
3,020.00
Ask:
3,044.00
Spread: 24.00 (0.795%)
Market Cap: £1.69b
OXIG Live PriceLast checked at - London Stock Exchange

Intraday Oxford Instruments Share Chart

Trading Update

13 Apr 2023 07:00

RNS Number : 0323W
Oxford Instruments PLC
13 April 2023
 

 

Oxford Instruments plc

Trading ahead of expectations for the full year

 

Oxford Instruments plc, a leading provider of high technology products and services to industry and scientific research communities, is today issuing a trading update for the year ended 31 March 2023 (FY23).

 

Ongoing global trends towards a greener, healthier and more connected advanced society have continued to drive strong growth in orders and revenue. This has resulted in good growth in a number of our chosen end markets, including life science, compound semiconductor, advanced materials and quantum technology.

 

Our increased focus on US, European and Japanese markets, underpinned by customer demand, has resulted in significant growth in orders and revenue across all three geographies. Orders and revenue from China have remained broadly in line with the prior year, despite Covid-related disruption and an increase in UK Government export licence refusals. Global supply chain challenges have continued, although, as anticipated, these began to improve in the second half of the financial year. As a result of these factors, Group revenue growth for the year is expected to be around 22% (14% at constant currency), with orders ahead of revenue for the year.

 

We anticipate that FY23 adjusted operating margin will remain broadly flat year-on-year, despite cost inflation and the previously stated lag in recovery through price increases, as well as our ongoing investment in delivery and efficiency. We continue to support our future growth ambitions and position ourselves to deliver process and cost efficiencies, by investing in reinforcing and extending capabilities across the business, including in infrastructure, IT, and resources.

 

Given our strong revenue growth, and supported by a currency tailwind, we expect adjusted operating profit for the full year ended 31 March 2023 to be ahead of our previous expectations.

 

Oxford Instruments' results for the year ending 31 March 2023 will be released on 13 June 2023.

 

 

Notes:

 

1. Adjusted operating profit is before amortisation and impairment of acquired intangible assets, acquisition items, other significant non-recurring items, and the mark-to-market revaluation of financial derivatives.

2. This Update contains forward-looking statements. These have been made in good faith based on the information available at the time of the directors' approval of this Update. The directors give no assurance that these expectations will prove to have been correct. Due to inherent uncertainties, including economic and business risk factors underlying such forward-looking information, actual results may differ materially from those expressed or implied by these forward-looking statements. The directors undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Enquiries:

 

Oxford Instruments plc

Ian Barkshire, Group Chief Executive

Gavin Hill, Chief Financial Officer

Julian Wais, Head of Investor Relations

Tel: 01865 393200

MHP Group

Katie Hunt / Eleni Menikou / Veronica Farah

oxfordinstruments@mhpgroup.com

Tel: 020 3128 8100

 

 

 

Notes to Editors  

 

About Oxford Instruments plc

Oxford Instruments designs, supplies andsupports high-technology products and systems which allow the world's leading companies and scientific research communities to image, analyse and manipulate materials down to the atomic and molecular level. The Group's products and services help its customers to accelerate R&D, increase manufacturing productivity and make ground-breaking discoveries across its key market segments: Semiconductor & Communications, Advanced Materials, Healthcare & Life Science, Energy & Environment and Quantum Technology.

Innovation is the driving force behind Oxford Instruments' growth and success, supporting its core purpose to enable a greener, healthier, more connected advanced society. Founded in 1959 as the first technology business to be spun out fromOxfordUniversity, Oxford Instruments is now a global company listed on the FTSE250 index of the London Stock Exchange (OXIG). Its customer-centric, market-focused strategy creates competitive advantage through understanding the technical and commercial challenges in markets with long-term structural growth drivers.

 

For more information, visit www.oxinst.com 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKBBKOBKDQQD
Date   Source Headline
5th Feb 20267:00 amPRNTransaction in Own Shares
4th Feb 20267:00 amPRNTransaction in Own Shares
3rd Feb 20267:00 amPRNTransaction in Own Shares
2nd Feb 20262:53 pmPRNTotal Voting Rights
2nd Feb 20267:59 amPRNTransaction in Own Shares
30th Jan 20267:00 amPRNTransaction in Own Shares
29th Jan 20267:00 amPRNTransaction in Own Shares
28th Jan 20267:00 amPRNTransaction in Own Shares
27th Jan 20267:00 amPRNTransaction in Own Shares
26th Jan 20267:00 amPRNTransaction in Own Shares
23rd Jan 20264:26 pmPRNHolding(s) in Company
22nd Jan 20267:00 amPRNTransaction in Own Shares
21st Jan 20267:00 amPRNTransaction in Own Shares
20th Jan 20267:00 amPRNTransaction in Own Shares
19th Jan 20269:39 amPRNHolding(s) in Company
15th Jan 20267:00 amRNSTrading Update
15th Jan 20267:00 amPRNTransaction in Own Shares
14th Jan 20262:15 pmPRNHolding(s) in Company
13th Jan 20264:15 pmPRNHolding(s) in Company
13th Jan 20267:00 amPRNTransaction in Own Shares
12th Jan 20267:00 amPRNTransaction in Own Shares
9th Jan 20267:00 amPRNTransaction in Own Shares
8th Jan 20267:00 amPRNTransaction in Own Shares
7th Jan 20267:00 amPRNTransaction in Own Shares
6th Jan 20267:00 amPRNTransaction in Own Shares
2nd Jan 202612:44 pmPRNBlock listing Interim Review
2nd Jan 202612:26 pmPRNTotal Voting Rights
23rd Dec 20253:32 pmRNSDirector/PDMR Shareholding
23rd Dec 20253:32 pmPRNDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSTransaction in Own Shares
22nd Dec 20257:00 amPRNTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amPRNTransaction in Own Shares
18th Dec 20257:00 amPRNTransaction in Own Shares
17th Dec 20253:16 pmPRNHolding(s) in Company
17th Dec 20257:00 amPRNTransaction in Own Shares
16th Dec 20257:00 amPRNTransaction in Own Shares
15th Dec 20257:00 amPRNTransaction in Own Shares
12th Dec 20257:00 amPRNTransaction in Own Shares
11th Dec 20257:00 amPRNTransaction in Own Shares
10th Dec 20257:00 amPRNTransaction in Own Shares
9th Dec 20257:00 amPRNTransaction in Own Shares
8th Dec 20252:37 pmPRNHolding(s) in Company
3rd Dec 20257:00 amPRNTransaction in Own Shares
2nd Dec 20257:00 amPRNTransaction in Own Shares
1st Dec 202510:37 amPRNTotal Voting Rights
1st Dec 20257:00 amPRNTransaction in Own Shares
28th Nov 20257:00 amPRNTransaction in Own Shares
27th Nov 20257:00 amPRNTransaction in Own Shares
26th Nov 20257:00 amPRNTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.